A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC).

• DOI: 10.1200/jco.2012.30.5_suppl.89
• Publication Date: 2017-02-23T18:53:34Z
• Authors: Susan Goodin; Mark N. Stein; Weichung Shih; Shou-En Lu; Xi Zheng; Monica Anand; Chandrika Jeyamohan; Tina M. Mayer; Robert A. Somer; Elisabeth Heath; Allan Conney; Robert S. DiPaola
• Keywords: Celecoxib; Combination therapy

89 Background: Single agent atorvastatin and celecoxib have been associated with reductions in the risk of PC. Our laboratories demonstrated that low doses drug combination synergistic effects inhibiting progression LNCaP tumors to androgen independence. We therefore sought determine androgen-dependent PC on PSA kinetics plasma correlates IL-6, C-reactive protein (CRP), PGE-2, pharmacokinetics validate preclinical biomarker findings. Methods: Patients rising after primary therapy for were enrolled. Patient must three values, each obtained at least 1 month apart. No prior hormone-ablative was allowed, except neoadjuvant setting or salvage XRT completed 3 months enrollment. any history coronary artery disease a previous myocardial infarction past 6 excluded. All patients treated 20 mg daily 200 twice day months. Paired pre-treatment treatment compared using Wilcoxon Signed Rank test. Results: report 14 therapy. Median pretreatment slope 0.14 log PSA/mo (median PSADT 4.98 mos), contrast median 0.09 7.37 mos); p=0.11. Eleven fourteen therapy, patient withdrew 2 stopped early due lack response. A declining observed one patient. The well tolerated, no clinically significant related toxicities ( > grade 1) reported 76 Conclusions: In this ongoing phase II trial, dose has tolerated demonstrates tendency increasing doubling time. Enrollment continues analysis CRP, PGE-2 be correlated individual clinical results.